Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) Share-based Compensation (IS): 2016-2025

Historic Share-based Compensation (IS) for AC Immune (ACIU) over the last 5 years, with Sep 2025 value amounting to -$350,021.

  • AC Immune's Share-based Compensation (IS) fell 161.51% to -$350,021 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 72.00%. This contributed to the annual value of $3.7 million for FY2023, which is 6.88% up from last year.
  • Per AC Immune's latest filing, its Share-based Compensation (IS) stood at -$350,021 for Q3 2025, which was down 178.11% from $448,127 recorded in Q2 2025.
  • AC Immune's Share-based Compensation (IS)'s 5-year high stood at $2.2 million during Q4 2022, with a 5-year trough of -$350,021 in Q3 2025.
  • Moreover, its 3-year median value for Share-based Compensation (IS) was $595,365 (2023), whereas its average is $617,000.
  • Per our database at Business Quant, AC Immune's Share-based Compensation (IS) soared by 68.66% in 2024 and then slumped by 161.51% in 2025.
  • AC Immune's Share-based Compensation (IS) (Quarterly) stood at $1.7 million in 2021, then climbed by 29.57% to $2.2 million in 2022, then fell by 9.09% to $2.0 million in 2023, then skyrocketed by 68.66% to $569,024 in 2024, then slumped by 161.51% to -$350,021 in 2025.
  • Its Share-based Compensation (IS) was -$350,021 in Q3 2025, compared to $448,127 in Q2 2025 and $441,563 in Q1 2025.